Sildenafil in Newborn Lung Crisis: Review Maps Dosing and Monitoring by Indication

Sildenafil, the drug best known for treating erectile dysfunction, has quietly become one of the most widely used rescue therapies in newborn intensive care units for dangerously high blood pressure in the lungs. A new narrative review published in Discover Pediatrics pulls together the scattered evidence on how the drug should be dosed, monitored and weaned in neonates, and it arrives at a nuanced conclusion: the drug is genuinely useful, but only with careful hemodynamic surveillance, individualized dosing and explicit weaning protocols.

Pulmonary hypertension in the newborn is a heterogeneous syndrome in which the pulmonary vascular bed fails to complete the normal postnatal drop in resistance that accompanies the transition to life outside the womb. Its principal forms are persistent pulmonary hypertension of the newborn, bronchopulmonary dysplasia-associated pulmonary hypertension, and postoperative pulmonary hypertension after congenital heart surgery. Together these conditions account for a disproportionate share of neonatal intensive care mortality. Persistent pulmonary hypertension alone affects roughly 1.9 per 1,000 live births in the United States, with reported mortality of 7 to 15 percent, and comparable or higher figures have emerged from Asian and Middle Eastern multicentre cohorts.

The established first-line treatment is inhaled nitric oxide, a selective pulmonary vasodilator that diffuses into vascular smooth muscle and triggers relaxation. But inhaled nitric oxide is expensive, logistically demanding and simply unavailable in a large proportion of neonatal units worldwide. Even where it is available, a substantial minority of treated neonates fail to respond, with some series reporting non-response approaching one-third to 40 percent, and withdrawal carries a recognized risk of rebound pulmonary hypertension. These gaps have driven widespread off-label use of sildenafil, an orally and intravenously bioavailable inhibitor of the enzyme phosphodiesterase type 5, either as an alternative when inhaled nitric oxide is unavailable, as an adjunct in non-responders, or as a bridge to ease weaning.

The biology behind the drug is well characterized. At birth, rising alveolar oxygen tension and lung inflation trigger endothelial nitric oxide production, which raises cyclic guanosine monophosphate inside pulmonary vascular smooth muscle cells and lowers cytosolic calcium, producing relaxation. Phosphodiesterase type 5 is the dominant enzyme degrading that messenger in the pulmonary vasculature. In disease states, reduced nitric oxide synthase activity, oxidative scavenging of nitric oxide and persistently elevated phosphodiesterase type 5 expression all conspire to reduce vasodilation. Sildenafil blocks the enzyme, restores the signaling pathway and lowers pulmonary arterial pressure. Although much of the upstream biology comes from animal models, the clinical effects of the drug, improved oxygenation and improved echocardiographic markers, have been corroborated in multiple human neonatal studies.

Neonatal pharmacokinetics differ sharply from those of older patients. Sildenafil is metabolized in the liver by CYP3A4 and, to a lesser extent, CYP2C9, producing an active metabolite that contributes about 20 percent of the parent drug’s activity. In term neonates, hepatic clearance is markedly reduced, giving an elimination half-life of approximately nine hours compared with three to four hours in adults, and clearance rises progressively over the first weeks of life as enzymes mature. Oral bioavailability, roughly 40 percent in adults, is more variable in critically ill newborns, where delayed gastric emptying, poor splanchnic perfusion, feed intolerance and vasopressor therapy can unpredictably alter absorption. No formal bioavailability study has been performed in critically ill neonates, so neonatal estimates are extrapolated from adult and older-infant data. This is why the intravenous route is increasingly preferred during acute hemodynamic instability, with transition to enteral therapy once the infant is stable and absorbing feeds reliably.

The strongest evidence base lies in persistent pulmonary hypertension of the newborn. A Cochrane review pooling five small randomized trials of 166 neonates found that sildenafil significantly improved oxygenation and reduced mortality in settings where inhaled nitric oxide was not available, with oral doses of 0.5 to 2 milligrams per kilogram every six hours producing oxygenation improvements within the first six to twelve hours. A network meta-analysis of 22 randomized trials covering more than 2,100 neonates identified intermediate oral doses of roughly 1 milligram per kilogram every six hours as offering the most favorable balance of efficacy and tolerability. For intravenous use, a dose-escalation study of 36 term and late-preterm neonates with oxygenation indices above 15 showed that a 0.4 milligram per kilogram loading dose over three hours followed by continuous infusion at 1.6 milligrams per kilogram per day reduced the oxygenation index from 28.7 to 19.3 within four hours. Notably, a subsequent phase 3 placebo-controlled trial of low-dose intravenous sildenafil added to optimized inhaled nitric oxide showed no benefit, underscoring that efficacy is dose-dependent and that simply adding a small dose does not guarantee additive gain.

The evidence is thinner elsewhere. In bronchopulmonary dysplasia-associated pulmonary hypertension, which affects roughly 20 to 25 percent of preterm infants with moderate-to-severe disease, the data are entirely observational: a retrospective cohort of 38 preterm infants showed reductions in estimated pulmonary arterial pressure on echocardiography, and a larger retrospective analysis of 188 infants reported echocardiographic improvement in about 88 percent of treated infants. In the post-cardiac-surgical setting, a randomized trial of 29 children including young infants found that prophylactic enteral sildenafil started before nitric oxide weaning significantly reduced rebound pulmonary hypertension, and retrospective neonatal series support low enteral or intravenous doses of 0.125 to 0.25 milligrams per kilogram per dose as a weaning bridge. The review rates the certainty of evidence as moderate for persistent pulmonary hypertension, low for bronchopulmonary dysplasia-associated disease, and moderate only for prevention of rebound during weaning in the surgical population.

Safety hinges on one dominant risk: systemic hypotension, arising from incomplete pulmonary vascular selectivity. In the intravenous dose-escalation study, hypotension occurred in roughly 30 percent of higher-dose cohorts and was generally responsive to volume expansion and vasopressors; in oral cohorts at conventional doses the reported incidence is lower, typically 5 to 10 percent. The risk concentrates in the first hours after initiation or dose escalation and in neonates with pre-existing vasodilation or sepsis. The review proposes a graded response: withhold or reduce the dose and correct reversible contributors, give a cautious volume bolus only if hypovolemia is suspected, and if rescue is needed use a vasopressor such as noradrenaline or vasopressin rather than a pure inotrope, reserving inotropes for documented myocardial dysfunction. Other reported effects include transient flushing, mild thrombocytopenia and gastrointestinal intolerance; priapism has not been a clinically significant problem in neonatal series, and small ophthalmological studies have not demonstrated persistent retinal abnormalities, though long-term ophthalmological and neurodevelopmental follow-up data remain lacking.

A shadow hangs over the field in the form of the 2012 warning from the United States Food and Drug Administration against routine sildenafil use in children aged 1 to 17 years, prompted by the STARTS-2 dose-ranging trial, in which higher oral doses were associated with a non-significant numerical increase in long-term mortality. The review argues that extrapolation to neonates is limited on several counts: the enrolled population was outside the neonatal age range, the trial used chronic ambulatory dosing over a median follow-up exceeding three years, the high-dose arm delivered weight-adjusted doses several-fold above the 8 milligrams per kilogram per day ceiling used in neonatal protocols, and the pathophysiology of older children differs substantively from transitional neonatal disease. A clinical advisory emphasized that the warning should not be read as a categorical contraindication for neonates at conventional doses. Regulatory positions still diverge: the United Kingdom’s regulator states that outside authorized indications sildenafil should not be used in neonates with persistent pulmonary hypertension because risks are considered to outweigh benefits, while the United States label simply notes that safety and effectiveness below one year of age are not established. The drug therefore remains off-label essentially everywhere, and the review stresses documented informed discussion with families rather than default use.

The review also maps a structured monitoring framework: continuous blood pressure and pre- and post-ductal oxygen saturation monitoring, baseline echocardiography, arterial blood gases and oxygenation indices every four to six hours in the first 48 hours, and, where available, serial B-type natriuretic peptide to track right ventricular afterload. A critical caveat runs through the whole document: failure to respond should trigger echocardiographic reassessment of the underlying physiology rather than reflexive dose escalation, because when elevated pulmonary pressures are predominantly post-capillary, from left heart dysfunction, or driven by shunt-related excess flow, vasodilators may be ineffective or harmful. Combination strategies with milrinone, bosentan or prostacyclin analogues rest on low or very low certainty evidence and carry additive hypotension risk. The authors are candid about the gaps: optimal dose, route and duration remain unestablished, long-term effects on the developing brain, retina and lung are incompletely characterized, and adequately powered neonatal-specific randomized trials, prospective registries and pharmacokinetic modeling across gestational ages remain the priorities for the next decade.

Subject of Research: Sildenafil dosing and monitoring in neonatal pulmonary hypertension

Article Title: A narrative review of sildenafil dosing and monitoring by indication in neonatal pulmonary hypertension

Article References: Menon, P. R., Sangdup, T., Edem, S., & Jha, P. (2026). A narrative review of sildenafil dosing and monitoring by indication in neonatal pulmonary hypertension. Discover Pediatrics, 1(1), Article 5. https://doi.org/10.1007/s44571-026-00005-5

Image Credits: AI Generated

DOI: 10.1007/s44571-026-00005-5

Keywords: sildenafil, neonatal pulmonary hypertension, PPHN, bronchopulmonary dysplasia, inhaled nitric oxide, PDE5 inhibitor, FDA warning, hypotension, monitoring, off-label use, resource-limited settings, pharmacokinetics